Royalty Report: Drugs, Cancer, Disease – Collection: 257483

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • cell therapy
  • Diagnostic
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 257483

License Grant
The Licensor of Switzerland grants an exclusive license under the Licensors Intellectual Property Rights, to develop, have developed, use, have used, sell, have sold, offer for sale, register, have registered, Commercialize, and have Commercialized and import the Product for any Indication in the Field of Use in the Territory.

This agreement includes a non-exclusive grant back to Licensor.

License Property
Licensor is a pharmaceutical company focused on the development of novel inhibitors of Pl3K6 for the treatment of various B-cell proliferative diseases.

Compound shall mean RP5264 or one of the twoBackup Compounds.

Products shall mean a pharmaceutical preparation in any formulation that contains the Compound as an active ingredient.

RP-5264 is in phase I clinical trials for the oral treatment of B-cell lymphoma and mantle cell lymphoma.

Field of Use
Field means the prevention, treatment or amelioration of any disease or condition in humans.

The Primary Indications means B-cell Lymphomas and Chronic Lymphocytic Leukemia.

IPSCIO Record ID: 280934

License Grant
This agreement is for development and commercialization of the clinical compound forodesine hydrochloride in markets across Europe, Asia and Australasia.

Licensor grants the Licensee of Bermuda an exclusive right and license in the Territory, with the right to sublicense, to Develop, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, under the Licensor Patents, Licensor Know-How and the Trademark.

Licensor grants during the Term of this Agreement a limited non-exclusive right to use the Licensor Logo on Promotional Literature in the Field in the Territory.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as PNP Inhibitors, including the compound known as __X-1777.

Licensed Products means all pharmaceutical preparations in all dosage strengths, formulations and methods of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient.

Trademark means the trademark Fodosine or such other trademark approved by the JDC for use in connection with the Licensed Products, but excluding the Secondary Marks.

B-cell Acute Lymphoblastic Leukemia/lymphoma or B-ALL means a disease in which certain cells of the B lymphocytes or B-cells are malignant, and have populated the bone marrow.

B-CLL means B-type chronic lymphocytic leukemia.

B-NHL means a Non-Hodgkin’s lymphoma in which the malignant cells have characteristics predominantly of the B lineage.

Field of Use
Field means the treatment of all Cancerous and/or Pre-Cancerous States in humans, specifically for the treatment of certain T-cell and B-cell mediated diseases in the area of oncology.
Fodosineâ„¢ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in a number of clinical trials including a Phase IIa clinical trial in patients with T-cell leukemia.

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 190857

License Grant
Licensor announced that the Centers for Medicare and Medicaid Services established a unique, product-specific billing code, J-code (J9034), for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, a chemotherapy drug used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
License Property
The original license agreement is for BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 266238

License Grant
The Company and Swiss Licensee amended the  terms of the License Agreement to increase the U.S. royalty paid to the Company and re-allocate certain litigation expenses of BENDEKA net United States sales, provided that BENDEKA’s orphan drug exclusivity has not been rescinded, withdrawn or waived by such date.  The Amendment also extends the U.S. royalty term for BENDEKA until it is no longer sold in the United States. The previous royalty term was set to expire in 2025.
License Property
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
BENDEKA™, the Company’s bendamustine hydrochloride rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma.

IPSCIO Record ID: 275366

License Grant
Licensor of Denmark grants Licensor of Switzerland. the remaining rights to ofatumumab.

The product, Ofatumumab, is being commercialized by Licensee.

License Property
The Product, ofatumumab, is marketed as Arzerra for certain indications of chronic lymphocytic leukemia (CLL).

Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).

Field of Use
Ofatumumab for the treatment of cancer and also for non-cancer treatments.  Ofatumumab, previously approved for certain CLL indications, is in pivotal Phase III testing by Licensee for the treatment of RMS, with the Phase III ASCLEPIOS I and II studies.

IPSCIO Record ID: 279359

License Grant
The Japanese Licensor grants an exclusive, even as to Licensor, right and license, with the right to grant sublicenses, in the field in the territory under Licensor Patent and Licensor Technical information to make, have made, develop, have developed, import, have imported, export, have exported, use, have used, offer to sell, sell, and have sold the Compound and/or the Product.
License Property
Licensor is the proprietor of certain patents and patent applications relating to the Compound and possesses technical information relating to the same.

Product shall mean any pharmaceutical preparation suitable for administration for human use containing the Compound as an active ingredient.

Compound shall mean the chemical compound [N-[3-(4,5-bipyrimidin-2-ylamino)-4-methylphenyl)-4-
{ [ (3S )-3-( dimethylamino) pyrrolidin- 1-yl) methyl}-3-(trifluoromethyl) benzamide], of which code name is designated as __-187.

Field of Use
NS-187 is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor. Bcr-Abl is commonly recognized as the primary molecular target in the treatment of CML.
Chronic myelogenous leukemia (CML) is a cancer that affects your blood cells and bone marrow — the soft part inside your bones where blood cells are made.

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents:
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

IPSCIO Record ID: 203264

License Grant
Licensor grants to the Japanese Licensee exclusive rights to the Products and certain backup compounds.

Licensor grants an exclusive license under the Licensors Technology to use and import Hematide in the Field in the Licensed Territory, to Develop, use, sell, offer for sale, and import the Bulk API, or Hematide in bulk form, and/or the Product in the Field in the Licensed Territory, and to make and have made the Finished Product anywhere in the world for such Development or sale in the Field in the Licensed Territory.  

Licensor grants to Licensee, during the Term, an exclusive license within the Licensed Territory to use and display the Product Trademarks and Licensors House Marks solely in the Promotional Materials and the Product Labeling in connection with the Commercialization of the Product within the Licensed Territory; provided that such license shall be co-exclusive with Licensor in the U.S. and further that Licensor may use such co-exclusive right solely for the Commercialization of the Product within the U.S. with Licensor.

License Property
“Product” means a pharmaceutical preparation in any formulation that contains Hematide.

“Product Trademark” means the mark “HEMATIDE” and any logos or symbols.

The technology refers to the Peptide, Dipeptide, Hematide, Product or their manufacture or use, or any other invention that is otherwise necessary or useful for the Development, Finished Manufacture or Commercialization of the Product.

Hematide, a synthetic, peptide-based, next-generation erythropoiesis- stimulating agent (ESA), is designed to stimulate the production of red blood cells. It is currently being evaluated in four Phase 2 clinical trials in the United States and Europe to treat anemia in chronic kidney disease (CKD) and cancer patients.

Hematide has a completely novel amino acid sequence that is unrelated to erythropoietin, a hormone that stimulates red blood cell formation, or to any other known naturally-occurring human sequences.

Field of Use
The Field means the prevention, treatment or amelioration of any disease or condition in humans.

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.

IPSCIO Record ID: 260439

License Grant
Licensor grants, with respect to the Field an exclusive, sole, worldwide license, with the right to grant sublicenses through multiple tiers of sublicenses, in, to, and under the Licensed Patents, Licensed Compounds, Licensed KnowHow, Licensed Process, and Licensed Product to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Compounds, Licensed Processes, and Licensed Products.
License Property
The patents include Novel compounds having a Benzoisoselen-azoline and -azine structure, method for preparating same and therapeutic uses thereof;   Aromatic Diselenides and Selenosulfides, their preparation and their uses, more particularly their therapeutical use;  and, Cyclic Organoselenium Compounds, their preparation and their uses.

The Licensed Compound shall mean a set of compounds having a benzoisoselenazoline and azine structure, and all derivatives, salts, enantiomers, crystal structures, metabolites, esters, and polymorphs, formulations and improvements thereof including a set of cyclic organoselenium compounds, each as disclosed and claimed in the Licensed Patents, for use in the Field.

The Licensed Process shall mean synthetic routes, materials, conditions, and/or processes relating to and for the manufacture of the Licensed Compounds and/or Licensed Product relating to the Field as disclosed in the Licensed Patents .

The Licensed Product shall mean any products prepared, created, generated or synthesized by use of the Licensed Process having Licensed Compound(s) as a primary active ingredient or agent which is disclosed and claimed in the Licensed Patents, including but not limited to BXT-51072, a licensed  compound, and the organoselenium compounds and formulations thereof disclosed and claimed in the Licensed Patents.

The new agreement expands the scope of a previous license to include non-cardiovascular indications.

Field of Use
The Field shall mean any and all uses including but not limited to the therapeutic, diagnostic, preventative, amerliorative, and/or prognostic for and in any indication, assay, disease and/or condition.

The patents cover a family of orally bioavailable organoselenium compounds that have shown anti-oxidant and anti-inflammatory properties in clinical and preclinical studies.

ALT-2074 (formerly BXT-51072), Licensee's lead compound under this license, is currently in a Phase 2 clinical study for cardiovascular indications.  By mimicking glutathione peroxidase (GPx), ALT-2074 may protect against excessive oxidation of lipids and thereby limit inflammation.  Licensee believes that the compound may be useful in patients with diabetes, whose cardiovascular disease may be caused by high levels of circulating oxidized lipids and associated inflammation.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.